<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="EN" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">ACS Sens</journal-id><journal-id journal-id-type="iso-abbrev">ACS Sens</journal-id><journal-id journal-id-type="pmc-domain-id">822</journal-id><journal-id journal-id-type="pmc-domain">acssd</journal-id><journal-id journal-id-type="publisher-id">se</journal-id><journal-title-group><journal-title>ACS Sensors</journal-title></journal-title-group><issn pub-type="epub">2379-3694</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>ACS AuthorChoice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8630787</article-id><article-id pub-id-type="pmcid-ver">PMC8630787.1</article-id><article-id pub-id-type="pmcaid">8630787</article-id><article-id pub-id-type="pmcaiid">8630787</article-id><article-id pub-id-type="pmid">34666481</article-id><article-id pub-id-type="doi">10.1021/acssensors.1c01024</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group><subject>Article</subject></subj-group></article-categories><title-group><article-title>Pentafluorosulfanyl (SF<sub>5</sub>) as a Superior <sup>19</sup>F Magnetic Resonance Reporter Group: Signal Detection and
Biological Activity of Teriflunomide Derivatives</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><name name-style="western"><surname>Prinz</surname><given-names initials="C">Christian</given-names></name><xref rid="aff1" ref-type="aff">&#8224;</xref><xref rid="aff2" ref-type="aff">&#8225;</xref></contrib><contrib contrib-type="author" id="ath2"><name name-style="western"><surname>Starke</surname><given-names initials="L">Ludger</given-names></name><xref rid="aff1" ref-type="aff">&#8224;</xref></contrib><contrib contrib-type="author" id="ath3"><name name-style="western"><surname>Ramspoth</surname><given-names initials="TF">Tizian-Frank</given-names></name><xref rid="aff3" ref-type="aff">&#167;</xref></contrib><contrib contrib-type="author" id="ath4"><name name-style="western"><surname>Kerkering</surname><given-names initials="J">Janis</given-names></name><xref rid="aff2" ref-type="aff">&#8225;</xref></contrib><contrib contrib-type="author" id="ath5"><name name-style="western"><surname>Martos Ria&#241;o</surname><given-names initials="V">Vera</given-names></name><xref rid="aff3" ref-type="aff">&#167;</xref></contrib><contrib contrib-type="author" id="ath6"><name name-style="western"><surname>Paul</surname><given-names initials="J">J&#233;r&#244;me</given-names></name><xref rid="aff3" ref-type="aff">&#167;</xref></contrib><contrib contrib-type="author" id="ath7"><name name-style="western"><surname>Neuenschwander</surname><given-names initials="M">Martin</given-names></name><xref rid="aff4" ref-type="aff">&#8741;</xref></contrib><contrib contrib-type="author" id="ath8"><name name-style="western"><surname>Oder</surname><given-names initials="A">Andreas</given-names></name><xref rid="aff4" ref-type="aff">&#8741;</xref></contrib><contrib contrib-type="author" id="ath9"><name name-style="western"><surname>Radetzki</surname><given-names initials="S">Silke</given-names></name><xref rid="aff4" ref-type="aff">&#8741;</xref></contrib><contrib contrib-type="author" id="ath10"><name name-style="western"><surname>Adelhoefer</surname><given-names initials="S">Siegfried</given-names></name><xref rid="aff1" ref-type="aff">&#8224;</xref></contrib><contrib contrib-type="author" id="ath11"><name name-style="western"><surname>Ramos Delgado</surname><given-names initials="P">Paula</given-names></name><xref rid="aff1" ref-type="aff">&#8224;</xref><xref rid="aff2" ref-type="aff">&#8225;</xref></contrib><contrib contrib-type="author" id="ath12"><name name-style="western"><surname>Aravina</surname><given-names initials="M">Mariya</given-names></name><xref rid="aff1" ref-type="aff">&#8224;</xref></contrib><contrib contrib-type="author" id="ath13"><name name-style="western"><surname>Millward</surname><given-names initials="JM">Jason M.</given-names></name><xref rid="aff1" ref-type="aff">&#8224;</xref><xref rid="aff2" ref-type="aff">&#8225;</xref></contrib><contrib contrib-type="author" id="ath14"><name name-style="western"><surname>Fillmer</surname><given-names initials="A">Ariane</given-names></name><xref rid="aff5" ref-type="aff">&#8869;</xref></contrib><contrib contrib-type="author" id="ath15"><name name-style="western"><surname>Paul</surname><given-names initials="F">Friedemann</given-names></name><xref rid="aff2" ref-type="aff">&#8225;</xref><xref rid="aff6" ref-type="aff">#</xref></contrib><contrib contrib-type="author" id="ath16"><name name-style="western"><surname>Siffrin</surname><given-names initials="V">Volker</given-names></name><xref rid="aff2" ref-type="aff">&#8225;</xref></contrib><contrib contrib-type="author" id="ath17"><name name-style="western"><surname>von Kries</surname><given-names initials="JP">Jens-Peter</given-names></name><xref rid="aff4" ref-type="aff">&#8741;</xref></contrib><contrib contrib-type="author" id="ath18"><name name-style="western"><surname>Niendorf</surname><given-names initials="T">Thoralf</given-names></name><xref rid="aff1" ref-type="aff">&#8224;</xref><xref rid="aff2" ref-type="aff">&#8225;</xref></contrib><contrib contrib-type="author" id="ath19"><name name-style="western"><surname>Nazar&#233;</surname><given-names initials="M">Marc</given-names></name><xref rid="aff3" ref-type="aff">&#167;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath20"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9916-9572</contrib-id><name name-style="western"><surname>Waiczies</surname><given-names initials="S">Sonia</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#8224;</xref><xref rid="aff2" ref-type="aff">&#8225;</xref></contrib><aff id="aff1"><label>&#8224;</label>Berlin
Ultrahigh Field Facility (B.U.F.F.), <institution>Max
Delbr&#252;ck Center for Molecular Medicine in the Helmholtz Association</institution>, Robert R&#246;ssle Stra&#223;e
10, 13125 Berlin, <country>Germany</country></aff><aff id="aff2"><label>&#8225;</label><institution>Experimental
and Clinical Research Center, a joint cooperation between the Charit&#233;
- Universit&#228;tsmedizin Berlin and the Max Delbr&#252;ck Center
for Molecular Medicine in the Helmholtz Association</institution>, Robert R&#246;ssle Stra&#223;e 10, 13125 Berlin, <country>Germany</country></aff><aff id="aff3"><label>&#167;</label>Medicinal
Chemistry, <institution>Leibniz-Institut f&#252;r Molekulare
Pharmakologie (FMP)</institution>, Robert R&#246;ssle Stra&#223;e 10, 13125 Berlin, <country>Germany</country></aff><aff id="aff4"><label>&#8741;</label>Screening
Unit, <institution>Leibniz-Institut f&#252;r Molekulare
Pharmakologie (FMP)</institution>, Robert R&#246;ssle Stra&#223;e 10, 13125 Berlin, <country>Germany</country></aff><aff id="aff5"><label>&#8869;</label><institution>Physikalisch-Technische
Bundesanstalt (PTB)</institution>, Abbestra&#223;e 2-12, 10587 Berlin, <country>Germany</country></aff><aff id="aff6"><label>#</label><institution>Charit&#233;
&#8722; Universit&#228;tsmedizin Berlin, corporate member of Freie
Universit&#228;t Berlin, Humboldt-Universit&#228;t zu Berlin,
and Berlin Institute of Health (BIH)</institution>, Charit&#233;platz 1, 10117 Berlin, <country>Germany</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>sonia.waiczies@mdc-berlin.de</email>.</corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>10</month><year>2021</year></pub-date><pub-date pub-type="ppub"><day>26</day><month>11</month><year>2021</year></pub-date><volume>6</volume><issue>11</issue><issue-id pub-id-type="pmc-issue-id">394640</issue-id><fpage>3948</fpage><lpage>3956</lpage><history><date date-type="received"><day>17</day><month>05</month><year>2021</year></date><date date-type="accepted"><day>24</day><month>09</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>11</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>01</day><month>12</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-04-03 12:25:16.773"><day>03</day><month>04</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2021 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>The Authors</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="se1c01024.pdf"/><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="ab-tgr1" position="float" orientation="portrait" xlink:href="se1c01024_0005.jpg"/></p><p>Fluorine (<sup>19</sup>F) magnetic
resonance imaging (MRI) is severely
limited by a low signal-to noise ratio (SNR), and tapping it for <sup>19</sup>F drug detection in vivo still poses a significant challenge.
However, it bears the potential for label-free theranostic imaging.
Recently, we detected the fluorinated dihydroorotate dehydrogenase
(DHODH) inhibitor teriflunomide (TF) noninvasively in an animal model
of multiple sclerosis (MS) using <sup>19</sup>F MR spectroscopy (MRS).
In the present study, we probed distinct modifications to the CF<sub>3</sub> group of TF to improve its SNR. This revealed SF<sub>5</sub> as a superior alternative to the CF<sub>3</sub> group. The value
of the SF<sub>5</sub> bioisostere as a <sup>19</sup>F MRI reporter
group within a biological or pharmacological context is by far underexplored.
Here, we compared the biological and pharmacological activities of
different TF derivatives and their <sup>19</sup>F MR properties (chemical
shift and relaxation times). The <sup>19</sup>F MR SNR efficiency
of three MRI methods revealed that SF<sub>5</sub>-substituted TF has
the highest <sup>19</sup>F MR SNR efficiency in combination with an
ultrashort echo-time (UTE) MRI method. Chemical modifications did
not reduce pharmacological or biological activity as shown in the
in vitro dihydroorotate dehydrogenase enzyme and T cell proliferation
assays. Instead, SF<sub>5</sub>-substituted TF showed an improved
capacity to inhibit T cell proliferation, indicating better anti-inflammatory
activity and its suitability as a viable bioisostere in this context.
This study proposes SF<sub>5</sub> as a novel superior <sup>19</sup>F MR reporter group for the MS drug teriflunomide.</p></abstract><kwd-group><kwd>SF<sub>5</sub></kwd><kwd>teriflunomide</kwd><kwd>DHODH</kwd><kwd>fluorine</kwd><kwd>MRI</kwd><kwd>MRS</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution>H2020 European Research Council</institution><institution-id institution-id-type="doi">10.13039/100010663</institution-id></institution-wrap></funding-source><award-id>743077</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Deutsche Forschungsgemeinschaft</institution><institution-id institution-id-type="doi">10.13039/501100001659</institution-id></institution-wrap></funding-source><award-id>DFG WA2804</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>se1c01024</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>se1c01024</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><p id="sec1">More than one-third of prescribed
drugs contain fluorine (<sup>19</sup>F), which generally improves
their pharmacokinetic properties.<sup><xref ref-type="bibr" rid="ref1">1</xref>&#8722;<xref ref-type="bibr" rid="ref5">5</xref></sup> Fluorination also opens an opportunity to noninvasively study drugs
in vivo using <sup>19</sup>F magnetic resonance imaging (MRI). This
prospect heralds an age when exact locations and concentrations of
drugs can be determined in patients to inform drug therapies.<sup><xref ref-type="bibr" rid="ref2">2</xref>&#8722;<xref ref-type="bibr" rid="ref8">8</xref></sup> The signal-to-noise ratio (SNR) achieved with <sup>19</sup>F MRI
is limited because of the low availability of <sup>19</sup>F nuclei
in vivo. Additionally, specific <sup>19</sup>F magnetic resonance
(MR) properties (chemical shift, spectral shape, e.g., full width
at half maximum or FWHM, spin&#8211;lattice (<italic toggle="yes">T</italic><sub>1</sub>) and spin&#8211;spin (<italic toggle="yes">T</italic><sub>2</sub>) relaxation
times) and pharmacological properties (metabolism, protein binding,
etc.) could influence SNR and <sup>19</sup>F MR signal detection.</p><p>The application of <sup>19</sup>F MRI continues to expand, e.g.,
to track immunotherapies,<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> investigate
temperature-dependent molecular switches,<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> image tumors using pH-responsive probes,<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> or monitor inflammatory processes in vivo.<sup><xref ref-type="bibr" rid="ref12">12</xref>,<xref ref-type="bibr" rid="ref13">13</xref></sup> The implications of <sup>19</sup>F MR methods to study physiological,
enzymatic, and other metabolic processes in vitro and in vivo have
long been recognized.<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref14">14</xref></sup> Molecular modifications involving
introduction of <sup>19</sup>F side groups have served several purposes,
e.g., as diagnostic biomarkers, where <sup>19</sup>F tracers or contrast
agents are implemented to interrogate function in biological systems.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup></p><p>Fluorinated drugs can be detected in vivo
using <sup>19</sup>F
MR spectroscopy (MRS) methods.<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> Recently,
we detected teriflunomide (TF), a dihydroorotate dehydrogenase (DHODH)
inhibitor, in an animal model of multiple sclerosis (MS) using nonlocalized <sup>19</sup>F MRS.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> TF inhibits the mitochondrial
DHODH enzyme that catalyzes the synthesis of the pyrimidine nucleotide
precursor orotate necessary for DNA replication, including CNS-specific
T cells that are key players in the MS pathology, thereby exerting
its anti-inflammatory action in MS.<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> Despite
recent advances to improve radiofrequency coil sensitivities,<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> there are still limitations that impede detection
of <sup>19</sup>F drugs in vivo with <sup>19</sup>F MRI or localized <sup>19</sup>F MRS, while these methods will be essential to locate drugs
within specific tissue and study their distribution in vivo. SNR was
a major limitation in our previous study due to the low TF availability
in vivo, thereby prohibiting imaging or localized MRS to specify its
location in vivo.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup></p><p>The pentafluorosulfanyl
(SF<sub>5</sub>) group has gained an immanent
role in organic materials, polymers, and liquid crystals and has also
recently emerged as a bioisostere for lipophilic groups like CF<sub>3</sub>, <italic toggle="yes">tert</italic>-butyl, halogen, or nitro groups in
biologically active compounds.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> SF<sub>6</sub> has been studied extensively in the gas phase as a diagnostic
tool for pulmonary <sup>19</sup>F MRI.<sup><xref ref-type="bibr" rid="ref20">20</xref>&#8722;<xref ref-type="bibr" rid="ref25">25</xref></sup> However, surprisingly, the corresponding derived organic -SF<sub>5</sub> group has thus far not been investigated as a <sup>19</sup>F MRI reporter group.</p><p>In this study, we investigated different
modifications to the CF<sub>3</sub> group of TF. This included the
addition of two symmetrical
CF<sub>3</sub> groups to increase the number of <sup>19</sup>F atoms
and the introduction of a SF<sub>5</sub> group and a trifluoromethoxy-group
to probe the effects of altering the chemical environment of <sup>19</sup>F atoms while leaving their number constant, to improve their
SNR and promote drug monitoring in vivo. In parallel, we also aimed
to preserve or even improve the pharmacological activity of TF. Generally,
the introduction of fluorine substituents enhances the potency of
DHODH inhibition of TF.<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> Here, the CF<sub>3</sub> group plays an important role in stabilizing the bioactive
conformation of TF.<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> The SF<sub>5</sub> group can be considered a bioisostere of CF<sub>3</sub>-groups in
drug compounds.<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> After a thorough characterization
of the pharmacological properties and <sup>19</sup>F MR properties
of the synthesized derivatives, we selected and optimized suitable
MR sequences, compared their SNR efficiency in imaging the derivatives,
and aligned this with their capacity to inhibit T cell proliferation.
Ultimately, we selected the best suited candidate for an ex vivo demonstration
of <sup>19</sup>F MRI in the murine stomach.</p><sec id="sec2"><title>Experimental
Section</title><sec id="sec2.1"><title>Synthesis of TF and Its Derivatives</title><p>Fluorinated anilines
were coupled with isoxazol acid chloride by a Schotten&#8211;Baumann
reaction,<sup><xref ref-type="bibr" rid="ref29">29</xref>,<xref ref-type="bibr" rid="ref30">30</xref></sup> and the isoxazol ring of the resulting leflunomide
prodrug structure was hydrolyzed for conversion into the teriflunomide
derivatives<sup><xref ref-type="bibr" rid="ref31">31</xref></sup> (Supporting Information:
Chemistry, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acssensors.1c01024/suppl_file/se1c01024_si_001.pdf">Figure S1</ext-link>). Derivatives of TF
(<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>) resulted
from a substitution of the <italic toggle="yes">para</italic> CF<sub>3</sub>-group
on the benzene ring with a trifluoromethoxy CF<sub>3</sub>O-R group,
two chemically symmetrical <italic toggle="yes">meta</italic> CF<sub>3</sub> groups,
and one <italic toggle="yes">para</italic> pentafluorosulfanyl SF<sub>5</sub> group.</p><fig id="fig1" position="float" orientation="portrait"><label>Figure 1</label><caption><p>Chemical
structures of the synthesized teriflunomide derivatives.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr1" position="float" orientation="portrait" xlink:href="se1c01024_0002.jpg"/></fig></sec><sec id="sec2.2"><title>Pharmacological Activity</title><p>The inhibitory activity of
TF derivatives on the DHODH enzyme was measured with a colorimetric
enzyme activity assay. Drug concentration ranged from 50 &#956;M
serially diluted in DMSO to 4.9 nM with a final DMSO concentration
of 1%. DHODH inhibition was studied by monitoring the reduction of
2,6-dichloroindophenol (DCIP) (Alfa Aesar) via color change (blue
to colorless, loss of absorbance at 620 nm). The colorimetric reaction
is associated with the oxidation of <sc>l</sc>-dihydroorotate (<sc>l</sc>-DHO) (Alfa Aesar) that is catalyzed by the DHODH enzyme.<sup><xref ref-type="bibr" rid="ref32">32</xref>&#8722;<xref ref-type="bibr" rid="ref35">35</xref></sup> The reaction was performed in duplicate in volumes of 30 &#956;L
in a 384-well plate in 50 mM tris&#8211;HCl buffer, containing 73
nM coenzyme Q10 (Selleckchem), 0.1% Triton X-100 (Sigma-Aldrich),
150 mM KCl (Sigma-Aldrich), 211 nM DCIP (Thermo Fisher), and 7.5 nM
DHODH (Biozol). The reaction was started by the addition of the substrate <sc>l</sc>-DHO, performed at 30 &#176;C, and monitored over 60 min using
a Tecan Safire2 Multimode Microplate Reader (Tecan).</p></sec><sec id="sec2.3"><title>Biological
Activity</title><p>The inhibitory activity of TF derivatives
on T cell proliferation was studied after isolating peripheral blood
mononuclear cells (PBMCs) from healthy volunteers. Informed, signed
consent was obtained for collecting blood samples. Approval was granted
from the ethics commission of the Charit&#233; (EA1/023/15). Compounds
were dissolved in DMSO (19 mM) and further diluted to final concentrations
ranging from 0.39 to 50 &#956;M.<sup><xref ref-type="bibr" rid="ref36">36</xref></sup> Compounds
(10 &#956;L) were plated on 96-well plates and stored at 4 &#176;C.</p><p>Blood (in EDTA) was withdrawn from two male healthy volunteers
(aged 25&#8211;35), diluted 1:2 in PBS, and layered on Lymphopure
(BioLegend) for separating cell populations using the principle of
Ficoll density gradient centrifugation (764 g, 40 min, RT, no brake).
PBMCs were cautiously collected from the corresponding phase and diluted
in PBS. After two washing steps in PBS, the cell pellet was resuspended
in a HEPES&#8211;RPMI 1640 buffer and counted using a Neubauer cell-counting
chamber.</p><p>Isolated PBMCs were labeled with carboxyfluoresceinsuccinimidylester
(CFSE) (BioLegend) as described elsewhere.<sup><xref ref-type="bibr" rid="ref37">37</xref></sup> The fluorescent dye CFSE is taken up into the cells. Dilutions of
CFSE in daughter cells (1:2 as a result of cell division) result in
sequential losses in fluorescence intensities. Labeling was performed
according to the manufacturer&#8217;s descriptions using 5 &#956;M
CFSE, and staining was quenched using a medium containing 10% FCS.
Cells were recounted and resuspended in a cell culture medium (5%
human AB serum, 1% GlutaMax (&#215;100, Gibco), 10 mM HEPES (Gibco),
and 1% penicillin (10 U/&#956;L)/streptomycin (10 &#956;g/&#956;L)
(Gibco) in an RPMI 1640 medium (Gibco)) at a concentration of 10<sup>6</sup> cells/mL. To induce T cell proliferation, isolated PBMCs
were incubated with the superantigen-similar polyclonal stimulating
reagent CytoStim (Miltenyi Biotec) following the manufacturer&#8217;s
instructions. CytoStim was added to the cell suspensions (0.2%).</p><p>Cells with or without CytoStim were distributed in 96-well plates
(in triplicate, with final volumes of 200 &#956;L per well) and kept
at 37 &#176;C and 5% CO<sub>2</sub> for 72 h. Wells without DHODH
inhibitors (TF or its derivates) served as positive proliferation
controls, and wells without T cell stimuli and inhibitors served as
negative controls. After incubation, cells were centrifuged, washed
with PBS, and resuspended in FACS buffer (0.5% BSA and 0.1% NaN<sub>3</sub> (Sigma-Aldrich) in PBS). Propidium iodide (PI) (BioLegend)
was added to each well approximately 5 min before the measurement
to stain the dead cell population. The fluorescence of CFSE labeling
and PI staining was analyzed by flow cytometry using a BD LSRFortessa
flow cytometer (BD Biosciences).</p></sec><sec id="sec2.4"><title>MR Methods</title><p>MR
experiments were performed on a 9.4 T
MR scanner (Bruker Biospec, Ettlingen, Germany). All DHODH inhibitors
(TF or its derivates) were diluted in either 100% DMSO (Roth) or 100%
human serum. The human serum was prepared from whole blood withdrawn
from a male healthy volunteer (aged 25) and allowed to stand for 15&#8211;30
min at room temperature; following centrifugation (21.1 g, 10 min,
RT), the supernatant (serum) was transferred into a new container.
Serum samples were stored at &#8722;20 &#176;C. Phantoms were prepared
in 2 and 1 mL syringes to characterize the spectra, chemical shifts,
relaxation times, and signal-to-noise (SNR) efficiencies. Teriflunomide
(Sigma-Aldrich and Genzyme) was used as a reference compound. Concentrations
of the compounds were adjusted as indicated in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acssensors.1c01024/suppl_file/se1c01024_si_001.pdf">Table S1</ext-link>.</p><p>For phantom experiments, a home-built dual-tunable <sup>19</sup>F/<sup>1</sup>H mouse head RF coil was used.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> MR measurements were performed at room temperature (RT).</p><p>A global single pulse spectroscopy (TR = 1000 ms, TA = 8 s, nominal
flip angle (FA) = 90&#176;, block pulse, 4096 points, dwell time =
0.02 ms, excitation pulse = 10,000 Hz, spectral bandwidth = 25,000
Hz) was used to detect the <sup>19</sup>F signal and to make frequency
adjustments. Chemical shifts are referenced to trichlorofluoromethane,
CFCl<sub>3</sub> (&#948;<sub>F</sub> = 0 ppm).</p><p>For determining <italic toggle="yes">T</italic><sub>1</sub> in low concentrated
serum samples, global spectroscopy with different TRs (TR = 50&#8211;8000
ms) was used. For spectroscopically determining <italic toggle="yes">T</italic><sub>2</sub>, a CPMG sequence was used (TR = 5000 ms, 25 echoes,
echo spacing = 2.8 ms, excitation pulse = 5000 Hz, spectral bandwidth
= 25,000 Hz).</p><p><italic toggle="yes">T</italic><sub>1</sub> mapping was performed
using RARE
(rapid acquisition with relaxation enhancement): TE = 4.6 ms, echo
train length (ETL) = 4, FOV = [16 &#215; 16] mm<sup>2</sup>, matrix
size = 64 &#215; 64, with 9 variable repetitions times (TR = 25&#8211;8000
ms). <italic toggle="yes">T</italic><sub>2</sub> mapping was performed using a
multislice multiecho sequence: TR = 2000 ms, FOV = [16 &#215; 16]
mm<sup>2</sup>, matrix size = 64 &#215; 64, with 25 different TEs
(TE = 40&#8211;1000 ms in steps of 40 ms for long <italic toggle="yes">T</italic><sub>2</sub> and TE = 8&#8211;200 ms in steps of 8 ms for short <italic toggle="yes">T</italic><sub>2</sub>).</p><p>To determine the most SNR efficient
MR technique for acquiring <sup>19</sup>F MRI of TF and its derivatives,
we optimized the parameters
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acssensors.1c01024/suppl_file/se1c01024_si_001.pdf">Table S3</ext-link>) of three MR sequences: RARE,
bSSFP (balanced steady-state free precession), and UTE (ultrashort
echo time). For all methods, the image geometry was set to FOV = [28
&#215; 28] mm<sup>2</sup>, matrix size = 96 &#215; 96 in DMSO, matrix
size = 64 &#215; 64 in serum, and slice thickness = 5 mm. Pulse sequence
parameters were optimized based on the relaxation times of each compound
in DMSO and serum.<sup><xref ref-type="bibr" rid="ref38">38</xref>,<xref ref-type="bibr" rid="ref39">39</xref></sup></p><p>For RARE, the receiver
bandwidth was set to 10 kHz to maximize
SNR but limit chemical shift artifacts. Centric encoding was used,
and the echo spacing was kept minimal for both long <italic toggle="yes">T</italic><sub>2</sub> conditions, i.e., in DMSO (TE<sub>DMSO</sub> = 12.12
ms), and short <italic toggle="yes">T</italic><sub>2</sub> conditions, i.e., in
serum (TE<sub>serum</sub> = 2.29 ms). For the latter condition, a
RARE sequence with gradient pulses optimized for short echo spacing
(RAREst) was used. We used a flip-back module and, based on simulations,
chose the highest possible ETL with a full width at half maximum (FWHM)
of the point spread function (PSF) below 1.5 pixels. Given these parameters,
we optimized the repetition time (TR) based on the steady state signal
intensity equation.<sup><xref ref-type="bibr" rid="ref38">38</xref></sup></p><p>For bSSFP,
the receiver bandwidth was set to 100 kHz to achieve
a short TR = 2.6 ms (TE = 1.3 ms) and thus stability regarding banding
artifacts. For each compound and condition, the flip angle &#945;<sub>bSSFP</sub> was adjusted to<disp-formula id="ueq1"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="se1c01024_m001.jpg"/></disp-formula></p><p>For UTE, we used an FID readout (TE = 0.27 ms) and a read
bandwidth
of 20 kHz. We used TR = 100 ms and the calculated Ernst angle &#945;<sub>E</sub> as the flip angle<disp-formula id="ueq2"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="se1c01024_m002.jpg"/></disp-formula></p><p>Animal experiments were conducted
in accordance with the procedures
approved by the Animal Welfare Department of the State Office for
Health and Social Affairs Berlin (LAGeSo) and conformed to guidelines
to minimize discomfort to animals (86/609/EEC).</p><p>The same molar
concentrations of TF (12.15 mg/mL) and SF<sub>5</sub>-TF (10 mg/mL)
suspended in 0.6% carboxymethyl cellulose were administered
orally (bolus volume of 800 &#956;L) to an anesthetized (intraperitoneal
injection, 7.5 mg/kg of xylazine and 100 mg/kg of ketamine in NaCl)
C57BL/6N mouse. After 20 min, the animal was sacrificed by an overdose
of the anesthetic, the esophagus and duodenum were closed with a surgical
suture, and the stomach was removed. An ex vivo phantom was prepared
in a 5 mL tube filled with 4% paraformaldehyde (Santa Cruz Biotechnology).
We used RARE for anatomical <sup>1</sup>H MRI of the stomach: TR/TE
= 2000 ms/10 ms; TA = 1 min, 4 s; FOV = [28 &#215; 28] mm<sup>2</sup>, and matrix = 256 &#215; 256, slice thickness = 0.5 mm, and an optimized
UTE sequence for <sup>19</sup>F MRI of TF and SF<sub>5</sub>-TF: TR/TE
= 100 ms/0.27 ms; TA = 2 h, 30 min, slice thickness = 5 mm, FA<sub>TF</sub> = 25&#176;, FA<sub>SF5-TF</sub> = 42&#176;, FOV =
[28 &#215; 28] mm<sup>2</sup>, and matrix = 32 &#215; 32.</p></sec><sec id="sec2.5"><title>Data Analysis</title><p>For DHODH activity, time&#8211;absorbance
curves reflect the enzymatic activity over time. We calculated the
initial slope of these curves to quantify the initial velocity of
the enzyme reaction. A <italic toggle="yes">Z</italic>&#8242; factor was calculated<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> using an in-house online <italic toggle="yes">Z</italic>&#8242;
calculator to assess the quality of the screening method (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.screeningunit-fmp.net/tools/z-prime.php">http://www.screeningunit-fmp.net/tools/z-prime.php</uri>). Screening assays with <italic toggle="yes">Z</italic>&#8242; values between
0.5 and 1 are categorized as excellent.<sup><xref ref-type="bibr" rid="ref40">40</xref></sup></p><p>For T cell proliferation, we analyzed flow cytometry data
using FlowJo (software version 10.5.3, FlowJo LLC, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acssensors.1c01024/suppl_file/se1c01024_si_001.pdf">Figure S2</ext-link>). The lymphocyte population was selected from the
forward (FSC-A)/sideward scatter (SSC-A) and gated for single cells
(FSC-A/FSC-H). Dead cells were excluded by gating for the cell population
SSC-A/PI without PI staining. From this population, the CFSE-labeled
cells were gated and displayed in a histogram, dividing the different
generations of cells from cell divisions. The percentage of proliferating
cells in relation to the originally labeled parental cell population
was calculated.</p><p>A <italic toggle="yes">Z</italic>&#8242; factor (see the
DHODH assay) was calculated
from the number of proliferating cells in unstimulated negative and
stimulated untreated positive controls. Additionally, the stimulation
index (SI) was determined from the proportion of proliferating cells
from nonproliferating ones<disp-formula id="ueq3"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="se1c01024_m003.jpg"/></disp-formula></p><p>Data from triplicates
from each donor were combined so that each
concentration point is represented by three measurement points.</p><p>MR image processing and spectral analysis and processing were performed
in MATLAB R2018a (MathWorks, Inc.). MR data was analyzed as detailed
in our previous work.<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> Briefly, we quantified
the spectral signal intensity, performed a Fourier transform to obtain
magnitude spectra, and determined the chemical shift. We estimated
the <italic toggle="yes">T</italic><sub>1</sub> and <italic toggle="yes">T</italic><sub>2</sub> time constants by fitting the measured signal intensities in MR
magnitude images to the equations for <italic toggle="yes">T</italic><sub>1</sub> and <italic toggle="yes">T</italic><sub>2</sub> relaxations. SNR estimations
for RARE, bSSFP, and UTE measurements and image preparation of ex
vivo samples were performed as previously described.<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> ImageJ<sup><xref ref-type="bibr" rid="ref43">43</xref></sup> was used for further
image analysis. We calculated the SNR efficiency (SNR/sqrt(time))
per mol to determine the compounds beneficial for in vivo application.</p></sec></sec><sec id="sec3"><title>Results and Discussion</title><sec id="sec3.1"><title>Inhibitory Activity of TF Derivatives In
Vitro</title><p>The
trifluoromethoxy-substituted TF (CF<sub>3</sub>O-TF) and pentafluorosulfanyl-substituted
TF (SF<sub>5</sub>-TF) demonstrated equal or even better pharmacological
and antiproliferative activities compared to TF (CF<sub>3</sub>-TF)
as shown by the IC<sub>50</sub> values for DHODH inhibition in in
vitro enzyme and proliferation assays (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>). We calculated the IC<sub>50</sub> values
for pharmacological DHODH inhibitory activity from dose&#8211;response
curves and by fitting a dose&#8211;response model to the data points
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acssensors.1c01024/suppl_file/se1c01024_si_001.pdf">Figure S3</ext-link>). The impact of TF and its derivates
to inhibit T cell proliferation was also determined from the IC<sub>50</sub> values from dose&#8211;response curves and by fitting a
dose&#8211;response model to the data points (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acssensors.1c01024/suppl_file/se1c01024_si_001.pdf">Figure S3</ext-link>). The T cell stimulation index yielded 47.3.</p><table-wrap id="tbl1" position="float" orientation="portrait"><label>Table 1</label><caption><title>IC<sub>50</sub> Values and Confidence
Intervals of the Enzyme Inhibition and Cell Proliferation Assays<xref rid="t1fn1" ref-type="table-fn">a</xref></title></caption><table frame="hsides" rules="groups" border="0"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th style="border:none;" align="center" colspan="1" rowspan="1">&#160;</th><th colspan="3" align="center" char="." rowspan="1">DHODH inhibition</th><th colspan="3" align="center" char="." rowspan="1">cell
proliferation inhibition</th></tr><tr><th style="border:none;" align="center" colspan="1" rowspan="1">compound</th><th style="border:none;" align="center" char="." colspan="1" rowspan="1">IC<sub>50</sub> [&#956;M]</th><th style="border:none;" align="center" char="." colspan="1" rowspan="1">lower limit
CI [&#956;M]</th><th style="border:none;" align="center" char="." colspan="1" rowspan="1">upper limit
CI [&#956;M]</th><th style="border:none;" align="center" char="." colspan="1" rowspan="1">IC<sub>50</sub> [&#956;M]</th><th style="border:none;" align="center" char="." colspan="1" rowspan="1">lower limit
CI [&#956;M]</th><th style="border:none;" align="center" char="." colspan="1" rowspan="1">upper limit
CI [&#956;M]</th></tr></thead><tbody><tr><td style="border:none;" align="left" colspan="1" rowspan="1">TF</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">0.54</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">0.32</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">0.77</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">24.25</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">19.01</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">29.52</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">CF<sub>3</sub>O-TF</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">0.33</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">0.11</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">0.55</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">10.98</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">8.65</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">13.31</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1"><italic toggle="yes">di</italic>-CF<sub>3</sub>-TF</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">1.32</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">0.53</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">2.11</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">39.73</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">6.88</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">72.60</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">SF<sub>5</sub>-TF</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">0.58</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">0.42</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">0.73</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">8.48</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">8.04</td><td style="border:none;" align="char" char="." colspan="1" rowspan="1">8.92</td></tr></tbody></table><table-wrap-foot><fn id="t1fn1"><label>a</label><p>The <italic toggle="yes">Z</italic>&#8242; value
for the proliferation assay was 0.893, which is comparable to the <italic toggle="yes">Z</italic>&#8217; value obtained in the enzyme inhibition assay.
A <italic toggle="yes">Z</italic>&#8242; value of &gt;0.5 confirms the robustness
of the assay. Therefore, unstimulated cells could be safely discriminated
from stimulated controls.</p></fn></table-wrap-foot></table-wrap><p>For TF and its derivatives, we calculated the IC<sub>50</sub> values
and 95% confidence intervals, for both DHODH and T cell proliferation
assays (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acssensors.1c01024/suppl_file/se1c01024_si_001.pdf">Figure S3</ext-link>). The activity of CF<sub>3</sub>O-TF to inhibit DHODH was marginally higher than that of TF
as shown by the lower IC<sub>50</sub>, while that of SF<sub>5</sub>-TF was similar, and that of the difluoromethyl-substituted <italic toggle="yes">di</italic>-CF<sub>3</sub>-TF was lower (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acssensors.1c01024/suppl_file/se1c01024_si_001.pdf">Figure S3</ext-link> and <xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>). In T cell proliferation experiments, both CF<sub>3</sub>O-TF and
SF<sub>5</sub>-TF showed a considerably greater inhibitory activity
than TF, as shown by the dose&#8211;response curves (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acssensors.1c01024/suppl_file/se1c01024_si_001.pdf">Figure S3B</ext-link>) and IC<sub>50</sub> values (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>). Compared to TF,
SF<sub>5</sub>-TF revealed the best inhibitory activity (IC<sub>50</sub> 8.48 &#956;M).</p><p>Substitution of the CF<sub>3</sub> group with
a SF<sub>5</sub> group
is expected to result in changes in the side chain geometry and electron
density. The SF<sub>5</sub> group is characterized by a higher electronegativity
and lipophilicity.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> The increased T cell
inhibitory activity by SF<sub>5</sub>-TF suggests an increased cellular
uptake in T cells as a result of more efficient permeation through
cell membranes due to increased lipophilicity, as has been shown in
trypanothione reductase inhibitors exhibiting increased cellular activity
and membrane permeability following introduction of SF<sub>5.</sub><sup><xref ref-type="bibr" rid="ref44">44</xref></sup></p><p>We also performed a cell growth
inhibition and cytotoxicity test
in HepG2 cells (Supporting Information: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acssensors.1c01024/suppl_file/se1c01024_si_001.pdf">Toxicology</ext-link>). All compounds showed a similar impact on cancer cell growth and
cytotoxicity to that of TF (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acssensors.1c01024/suppl_file/se1c01024_si_001.pdf">Figure S4</ext-link>).
While T cell inhibitory activity of SF<sub>5</sub>-TF was enhanced,
its impact on cytotoxicity was similar to that of TF. Furthermore,
nucleic acid staining using propidium iodide (PI) did not reveal cytotoxic
effects in T cells, even at higher concentrations (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acssensors.1c01024/suppl_file/se1c01024_si_001.pdf">Figure S5</ext-link>).</p></sec><sec id="sec3.2"><title><sup>19</sup>F MR Relaxation and Chemical
Shifts of TF Derivatives</title><p>We studied the <sup>19</sup>F MR
properties of all TF derivatives
in DMSO and in human serum. We used serum to simulate the in vivo
situation. When TF is administered to patients, it becomes strongly
protein bound (e.g., in blood, it is &gt;99% bound to protein<sup><xref ref-type="bibr" rid="ref45">45</xref></sup>). Since the solubility of TF compounds in serum
was lower than in DMSO, lower concentrations of TF compounds were
available in serum (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acssensors.1c01024/suppl_file/se1c01024_si_001.pdf">Table S1</ext-link>); this resulted
in an expected lower SNR (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acssensors.1c01024/suppl_file/se1c01024_si_001.pdf">Figure S6</ext-link>). TF,
CF<sub>3</sub>O-TF, and <italic toggle="yes">di</italic>-CF<sub>3</sub>-TF exhibit
a single peak at &#8722;58, &#8722;55, and &#8722;59 ppm, respectively,
in DMSO (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>).
SF<sub>5</sub>-TF shows a main peak at 67.4 ppm and a smaller peak
at 91.7 ppm at a ratio of 4:1 (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acssensors.1c01024/suppl_file/se1c01024_si_001.pdf">Figure S7</ext-link>). Due to
the geometric orientation of the five fluorine atoms to the phenyl
moiety, one positioned axially and four in equatorial positions, the
main peak shows a line splitting (doublet) and the smaller peak shows
an apparent 1:4:6:4:1 intensity pentet (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acssensors.1c01024/suppl_file/se1c01024_si_001.pdf">Figure S7</ext-link>).<sup><xref ref-type="bibr" rid="ref46">46</xref></sup></p><fig id="fig2" position="float" orientation="portrait"><label>Figure 2</label><caption><p><sup>19</sup>F MR spectra
of teriflunomide and its derivatives.
Signal acquired (normalized amplitudes) from compounds dissolved in
DMSO (upper panels) or human serum (lower panels) obtained by a global
single-pulse spectroscopy (TR = 1000 ms and TA = 8000 ms).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr2" position="float" orientation="portrait" xlink:href="se1c01024_0003.jpg"/></fig><p>Spectra of the compounds solubilized in serum were similar
to those
in DMSO; although we observed a slight change in the chemical shift
and peak broadening (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>, lower panels), also quantified from the full width at half
maximum (FWHM) of the peaks (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acssensors.1c01024/suppl_file/se1c01024_si_001.pdf">Table S2</ext-link>).</p><p>Interestingly, increasing the number of fluorine atoms on a drug
structure is not the only factor that affects the effective SNR. Our
results indicate that addition of the SF<sub>5</sub>-group to the
molecular structure reduces both the transversal relaxation time <italic toggle="yes">T</italic><sub>2</sub> and longitudinal relaxation time <italic toggle="yes">T</italic><sub>1</sub>.</p><p>Spin&#8211;lattice relaxation times (<italic toggle="yes">T</italic><sub>1</sub>) were measured for all TF derivatives (<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>). Compared to TF
in DMSO, <italic toggle="yes">di</italic>-CF<sub>3</sub>-TF had an almost equal <italic toggle="yes">T<sub>1</sub></italic> relaxation time, CF<sub>3</sub>O-TF had a
prolonged <italic toggle="yes">T<sub>1</sub></italic> relaxation time, and SF<sub>5</sub>-TF had a substantially
reduced <italic toggle="yes">T<sub>1</sub></italic> relaxation time. In serum, <italic toggle="yes">T</italic><sub>1</sub> was equal for TF but was reduced for CF<sub>3</sub>O-TF, <italic toggle="yes">di</italic>-CF<sub>3</sub>-TF, and SF<sub>5</sub>-TF, compared to the same compounds in DMSO.</p><table-wrap id="tbl2" position="float" orientation="portrait"><label>Table 2</label><caption><title>Comparison
of <italic toggle="yes">T</italic><sub>1</sub> and <italic toggle="yes">T</italic><sub>2</sub> Relaxation Times in DMSO
and Serum of TF and Its Derivatives to Optimize the SNR Efficiency
of the <sup>19</sup>F MR Acquisition Method</title></caption><table frame="hsides" rules="groups" border="0"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th style="border:none;" align="center" colspan="1" rowspan="1">&#160;</th><th colspan="2" align="center" rowspan="1"><italic toggle="yes">T</italic><sub>1</sub> (ms)</th><th colspan="2" align="center" rowspan="1"><italic toggle="yes">T</italic><sub>2</sub> (ms)</th></tr><tr><th style="border:none;" align="center" colspan="1" rowspan="1">compound</th><th style="border:none;" align="center" colspan="1" rowspan="1">DMSO</th><th style="border:none;" align="center" colspan="1" rowspan="1">serum</th><th style="border:none;" align="center" colspan="1" rowspan="1">DMSO</th><th style="border:none;" align="center" colspan="1" rowspan="1">serum</th></tr></thead><tbody><tr><td style="border:none;" align="left" colspan="1" rowspan="1">TF</td><td style="border:none;" align="left" colspan="1" rowspan="1">1003</td><td style="border:none;" align="left" colspan="1" rowspan="1">1017</td><td style="border:none;" align="left" colspan="1" rowspan="1">508</td><td style="border:none;" align="left" colspan="1" rowspan="1">5</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">CF<sub>3</sub>O-TF</td><td style="border:none;" align="left" colspan="1" rowspan="1">1666</td><td style="border:none;" align="left" colspan="1" rowspan="1">753</td><td style="border:none;" align="left" colspan="1" rowspan="1">942</td><td style="border:none;" align="left" colspan="1" rowspan="1">8</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1"><italic toggle="yes">di</italic>-CF<sub>3</sub>-TF</td><td style="border:none;" align="left" colspan="1" rowspan="1">1098</td><td style="border:none;" align="left" colspan="1" rowspan="1">875</td><td style="border:none;" align="left" colspan="1" rowspan="1">642</td><td style="border:none;" align="left" colspan="1" rowspan="1">5</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">SF<sub>5</sub>-TF</td><td style="border:none;" align="left" colspan="1" rowspan="1">371</td><td style="border:none;" align="left" colspan="1" rowspan="1">331</td><td style="border:none;" align="left" colspan="1" rowspan="1">68</td><td style="border:none;" align="left" colspan="1" rowspan="1">6</td></tr></tbody></table></table-wrap><p>Spin&#8211;spin relaxation times (<italic toggle="yes">T</italic><sub>2</sub>) were also measured for all compounds (<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>). Compared to TF
in DMSO, CF<sub>3</sub>O-TF and <italic toggle="yes">di</italic>-CF<sub>3</sub>-TF had longer spin&#8211;spin
relaxations, while SF<sub>5</sub>-TF had a markedly shorter spin&#8211;spin
relaxation. The <italic toggle="yes">T</italic><sub>2</sub> in serum also dramatically
dropped to values between 5 and 8 ms.</p><p>While a reduction in <italic toggle="yes">T</italic><sub>2</sub> requires MR
methods with faster signal acquisition (e.g., UTE), a reduction in <italic toggle="yes">T</italic><sub>1</sub> reduces the time required between different
excitations, thereby enabling more efficient data acquisition. The
reductions in relaxation times could be attributed to dipole&#8211;dipole
interactions and chemical shift anisotropy.<sup><xref ref-type="bibr" rid="ref47">47</xref>,<xref ref-type="bibr" rid="ref48">48</xref></sup> Besides modifications of side chains, the addition of a paramagnetic
dopant such as lanthanide chelates, in particular, gadolinium-containing
contrast agents, has been used for shortening the <italic toggle="yes">T</italic><sub>1</sub><italic toggle="yes">.</italic>(<xref ref-type="bibr" rid="ref49">49</xref>) For <sup>19</sup>F MR applications, <sup>19</sup>F nanoparticles were functionalized
with Gd(III) complexes for modulating the <sup>19</sup>F signal.<sup><xref ref-type="bibr" rid="ref50">50</xref></sup> Increased <sup>19</sup>F MR signals from <sup>19</sup>F nanoparticles were observed in close proximity to blood&#8211;brain
barrier disruptions, indicating a <italic toggle="yes">T</italic><sub>1</sub> shortening
effect not only for <sup>1</sup>H but also for<sup>19</sup>F as a
result of the paramagnetic contrast agent Gd&#8211;DTPA leakage.<sup><xref ref-type="bibr" rid="ref51">51</xref></sup></p></sec><sec id="sec3.3"><title>Impact of Serum on <sup>19</sup>F MR Relaxation</title><p>Differences
in chemical shifts and relaxation times can be attributed to the different
physicochemical properties of the <sup>19</sup>F groups. These properties
were also severely affected by the serum environment. SF<sub>5</sub>-TF is administered as a suspension, and SF<sub>6</sub> is administered
as a gas. All six fluorines on SF<sub>6</sub> produce one signal,
whereas the SF<sub>5</sub> group has an AX4 spin system and produces
two separate signals. Most notably, the <sup>19</sup>F <italic toggle="yes">T</italic><sub>2</sub> relaxation times of TF and its derivatives were drastically
shortened in serum. The increase in FWHM of the <sup>19</sup>F MR
spectra in the serum compared to DMSO also suggests a <italic toggle="yes">T</italic><sub>2</sub><italic toggle="yes">*</italic> shortening.<sup><xref ref-type="bibr" rid="ref52">52</xref></sup> The observed shortening in relaxation is presumably attributed to
unspecific binding of the compounds to serum proteins.<sup><xref ref-type="bibr" rid="ref53">53</xref></sup> Similar to SF<sub>5</sub>-substituted TF, the
fluorinated gas SF<sub>6</sub> exhibits a short transversal relaxation
time.<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> SF<sub>5</sub> is an organic derivative
of SF<sub>6</sub> in which one of the fluorine atoms is replaced by
an organic residue. However, there are notable <italic toggle="yes">T</italic><sub>1</sub> and <italic toggle="yes">T</italic><sub>2</sub> differences between SF<sub>5</sub>-TF and SF<sub>6</sub>.<sup><xref ref-type="bibr" rid="ref20">20</xref>,<xref ref-type="bibr" rid="ref21">21</xref></sup> At 9.4 T, the <italic toggle="yes">T</italic><sub>1</sub> of SF<sub>6</sub> at room temperature (300
K) was reported to be &lt;200 ms<sup><xref ref-type="bibr" rid="ref21">21</xref></sup> and
is even shorter (1.24 ms at 1.9 T) when administered to rats as a
gas (80%, 630 Torr barometric pressure).<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> The <italic toggle="yes">T</italic><sub>1</sub> of SF<sub>5</sub>-TF was not
strongly reduced in the presence of serum (<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>), and we would expect similar values for
this compound in vivo. On the other hand, the <italic toggle="yes">T</italic><sub>2</sub> of SF<sub>5</sub>-TF was strongly reduced (by 90%) in the
presence of serum. Differences between SF<sub>5</sub>-TF and SF<sub>6</sub> with respect to <italic toggle="yes">T</italic><sub>1</sub> and <italic toggle="yes">T</italic><sub>2</sub> can be attributed to differences in chemical
environments.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup></p><p>Recently, we could
detect TF in vivo when employing <sup>19</sup>F MRS.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> The above limitations in relaxation times, particularly
when protein bound, restrict SNR. Due to the associated rapid loss
in <sup>19</sup>F signal during <italic toggle="yes">T</italic><sub>2</sub> relaxation,
signal detection with <sup>19</sup>F MRI is expected to be more challenging.</p></sec><sec id="sec3.4"><title>Optimization of <sup>19</sup>F MR Parameters</title><p>We used
the determined <sup>19</sup>F relaxation times for TF and its derivatives
to calculate the most efficient parameters for three <sup>19</sup>F MRI acquisition methods: rapid acquisition with relaxation enhancement
(RARE), balanced steady-state free precession (SSFP), and ultrashort
echo time (UTE) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acssensors.1c01024/suppl_file/se1c01024_si_001.pdf">Table S3</ext-link>). Selection of
the appropriate MR acquisition method according to the MR properties
of the compound within a specific environment is essential to acquire
data with the best SNR efficiency. A thorough characterization of <sup>19</sup>F compounds<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> is typically necessary
to adapt SNR efficient <sup>19</sup>F MR acquisition methods to the
specific MR characteristics of these compounds.<sup><xref ref-type="bibr" rid="ref38">38</xref></sup></p><p>We acquired <sup>19</sup>F MR images of all compounds
using the corresponding optimized sequences (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acssensors.1c01024/suppl_file/se1c01024_si_001.pdf">Figure S6</ext-link>) and compared SNR efficiencies (SNR per molecule divided
by the square root of the acquisition time) to identify the most suited
method for each compound, in DMSO and in serum (<xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">3</xref></xref>). In DMSO, RARE yielded the best SNR efficiency
for all compounds, followed by bSSFP and UTE. In DMSO, <italic toggle="yes">di</italic>-CF<sub>3</sub>-TF showed the best SNR efficiency performance compared
to TF. In serum, UTE was the MR acquisition method that provided the
best SNR efficiency for all TF compounds, particularly for SF<sub>5</sub>-TF. The SF<sub>5</sub>-substituted derivative showed a gain
in <sup>19</sup>F SNR efficiency of &#8764;3 compared to TF when
using the UTE <sup>19</sup>F MRI method. This translates into a 9-fold
reduction in measurement time, which is the primary obstacle of <sup>19</sup>F MRI for both clinical and preclinical applications. In
addition, the SF<sub>5</sub>-TF also showed an increase of &#8764;3
in inhibiting T cell proliferation.</p><table-wrap id="tbl3" position="float" orientation="portrait"><label>Table 3</label><caption><title>SNR Comparison Using
Optimized RARE,
bSSFP, and UTE Protocols Studying the SNR Efficiency of Compounds
(Using SNR per Molecule) in DMSO and in Serum (in % Normalized to
TF RARE)</title></caption><table frame="hsides" rules="groups" border="0"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th style="border:none;" align="center" colspan="1" rowspan="1">&#160;</th><th colspan="2" align="center" rowspan="1">RARE</th><th colspan="2" align="center" rowspan="1">bSSFP</th><th colspan="2" align="center" rowspan="1">UTE</th></tr><tr><th style="border:none;" align="center" colspan="1" rowspan="1">compound</th><th style="border:none;" align="center" colspan="1" rowspan="1">DMSO</th><th style="border:none;" align="center" colspan="1" rowspan="1">serum</th><th style="border:none;" align="center" colspan="1" rowspan="1">DMSO</th><th style="border:none;" align="center" colspan="1" rowspan="1">serum</th><th style="border:none;" align="center" colspan="1" rowspan="1">DMSO</th><th style="border:none;" align="center" colspan="1" rowspan="1">serum</th></tr></thead><tbody><tr><td style="border:none;" align="left" colspan="1" rowspan="1">TF</td><td style="border:none;" align="left" colspan="1" rowspan="1">100</td><td style="border:none;" align="left" colspan="1" rowspan="1">100</td><td style="border:none;" align="left" colspan="1" rowspan="1">63</td><td style="border:none;" align="left" colspan="1" rowspan="1">9</td><td style="border:none;" align="left" colspan="1" rowspan="1">17</td><td style="border:none;" align="left" colspan="1" rowspan="1">163</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">CF<sub>3</sub>O-TF</td><td style="border:none;" align="left" colspan="1" rowspan="1">106</td><td style="border:none;" align="left" colspan="1" rowspan="1">101</td><td style="border:none;" align="left" colspan="1" rowspan="1">55</td><td style="border:none;" align="left" colspan="1" rowspan="1">20</td><td style="border:none;" align="left" colspan="1" rowspan="1">14</td><td style="border:none;" align="left" colspan="1" rowspan="1">148</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1"><italic toggle="yes">di</italic>-CF<sub>3</sub>-TF</td><td style="border:none;" align="left" colspan="1" rowspan="1">200</td><td style="border:none;" align="left" colspan="1" rowspan="1">162</td><td style="border:none;" align="left" colspan="1" rowspan="1">130</td><td style="border:none;" align="left" colspan="1" rowspan="1">34</td><td style="border:none;" align="left" colspan="1" rowspan="1">33</td><td style="border:none;" align="left" colspan="1" rowspan="1">240</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1">SF<sub>5</sub>-TF</td><td style="border:none;" align="left" colspan="1" rowspan="1">68</td><td style="border:none;" align="left" colspan="1" rowspan="1">76</td><td style="border:none;" align="left" colspan="1" rowspan="1">74</td><td style="border:none;" align="left" colspan="1" rowspan="1">26</td><td style="border:none;" align="left" colspan="1" rowspan="1">32</td><td style="border:none;" align="left" colspan="1" rowspan="1">363</td></tr></tbody></table></table-wrap><p>One interpretation
of these results is that the increased activity
of SF<sub>5</sub>-TF could allow a lower dose to be used while maintaining
the same level of therapeutic efficacy. However, a randomized clinical
study following 12&#8211;14 years of TF treatment showed that a larger
proportion of MS patients (51.5%) were relapse-free when receiving
14 mg of teriflunomide, compared to those receiving 7 mg of TF (39.5%).<sup><xref ref-type="bibr" rid="ref54">54</xref>,<xref ref-type="bibr" rid="ref55">55</xref></sup> Thus, the higher efficacy of SF<sub>5</sub>-TF might have downstream
benefits for MS patients, and future in vivo experiments in the animal
model will be needed to clarify whether SF<sub>5</sub>-TF administered
at the same dose as TF will be more efficacious at treating neurological
diseases. Apart from a &#8764;3&#215; gain in the <sup>19</sup>F
SNR efficiency in vitro, we observed an SNR gain of &#8764;2 for
SF<sub>5</sub>-TF compared to TF in the stomach ex vivo. This variation
in the SNR gain could reflect variations in pH in the stomach that
could affect relaxation times of TF.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> Future
comparative studies are needed to focus on organ systems more relevant
to the pathophysiology of MS such as the CNS.</p></sec><sec id="sec3.5"><title>Biological and <sup>19</sup>F MR Reporter Activities of TF Compounds</title><p>We aligned the
biological activity with SNR efficiency of all <sup>19</sup>F MRI
acquisition methods when comparing TF with its substituted
derivatives (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>A). Compared to all compounds, SF<sub>5</sub>-TF showed a clear enhancement
in the T cell proliferation inhibitory activity, as well as SNR efficiency
under serum conditions when using a UTE sequence. We administered
TF and SF<sub>5</sub>-TF orally to C57BL/6 mice using the same molar
concentrations (TF =12.15 mg/mL (<italic toggle="yes">n</italic> = 3) and SF<sub>5</sub>-TF = 10 mg/mL (<italic toggle="yes">n</italic> = 3)) and acquired <sup>19</sup>F MR images of the stomachs ex vivo using the optimized parameters
(<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>B,C). We observed
a clear distribution of both TF and SF<sub>5</sub>-TF in the stomach
and measured peak SNR values of 13.2 &#177; 1.2 (mean &#177; maximum
absolute deviation) for SF<sub>5</sub>-TF in the stomach, compared
to 5.8 &#177; 2.9 for TF (MR Characterization, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acssensors.1c01024/suppl_file/se1c01024_si_001.pdf">Figure S8 and Table S4</ext-link>).</p><fig id="fig3" position="float" orientation="portrait"><label>Figure 3</label><caption><p>Biological and <sup>19</sup>F MR reporter
activities of TF compounds.
(A) Selecting the best <sup>19</sup>F TF derivative and corresponding
MR acquisition method. Drug compounds with the best inhibitory capacity
(inverse IC<sub>50</sub> normalized to TF in percentage) and best
SNR efficiency in serum (normalized to TF in percentage using a RARE
sequence) obtained using RARE, bSSFP, and UTE sequences are shown
in the upper right quadrant (orange region). (B)<sup>19</sup>F MR
reporter activity of TF in the stomach of a C57BL/6 mouse ex vivo
using an optimized <sup>19</sup>F UTE MR sequence. Left panel: <sup>1</sup>H anatomical image of the stomach, middle panel: <sup>19</sup>F MRI of TF in the stomach, and right panel: <sup>19</sup>F/<sup>1</sup>H overlay. <sup>1</sup>H: RARE (TR/TE = 2000 ms/10 ms, TA
= 1 min, 4 s) and <sup>19</sup>F: UTE (TR/TE = 100 ms/0.27 ms, TA
= 2 h, 30 min, FA = 25 &#176;). (C) <sup>19</sup>F MR reporter activity
of SF<sub>5</sub>-TF in the stomach of a C57BL/6 mouse ex vivo using
an optimized <sup>19</sup>F UTE MR sequence. Left panel: <sup>1</sup>H anatomical image of the stomach<italic toggle="yes">,</italic> middle panel: <sup>19</sup>F MRI of SF<sub>5</sub>-TF in the stomach, and right panel: <sup>19</sup>F/<sup>1</sup>H overlay. <sup>1</sup>H: RARE (TR/TE = 2000
ms/10 ms, TA = 1 min, 4 s) and <sup>19</sup>F: UTE (TR/TE = 100 ms/0.27
ms, TA = 2 h, 30 min, FA = 42 &#176;). SNR is indicated by the color
bars.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr3" position="float" orientation="portrait" xlink:href="se1c01024_0004.jpg"/></fig></sec></sec><sec id="sec4"><title>Conclusions</title><p>In
this study, we introduced modifications, including those of
SF<sub>5</sub>, to a pharmacologically active compound, to increase
detection in vivo. To our knowledge, this is the first study that
has performed an in-depth investigation of <sup>19</sup>F modifications
on pharmacological and biological activities, alongside the MR reporter
function. Here, we addressed SNR by modifying the CF<sub>3</sub> side
chain of TF to vary the <sup>19</sup>F MR properties and identify
potential SNR-boosting derivatives. Substituting the CF<sub>3</sub> side chain by CF<sub>3</sub>O, SF<sub>5</sub>, or <italic toggle="yes">di</italic>-CF<sub>3</sub> did not compromise the pharmacological and antiproliferative
activities. Of note, the superiority of the SF<sub>5</sub>-substituted
derivative to inhibit T cell proliferation compared to TF indicates
that some fluorination strategies might even improve the biological
function.</p><p>Our study indicates SF<sub>5</sub> as a potential
theranostic marker
for detecting and studying the biodistribution of fluorinated drugs
noninvasively, particularly during pathology. However, in vivo studies
will now be necessary to study the versatility of the SF<sub>5</sub> bioisostere in combination with the UTE method for in vivo <sup>19</sup>F MRI and to determine its superiority over teriflunomide
to treat disease in the animal model of multiple sclerosis.</p></sec></body><back><notes id="notes1" notes-type="si"><title>Supporting Information Available</title><p>The Supporting
Information is
available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acssensors.1c01024?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acssensors.1c01024</ext-link>.<list id="silist" list-type="simple"><list-item><p>Supplemental methods and
results (chemistry, flow cytometry,
enzyme and T cell growth inhibition, toxicology, and MR characterization)
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acssensors.1c01024/suppl_file/se1c01024_si_001.pdf">PDF</ext-link>)</p></list-item></list></p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="se1c01024_si_001.pdf" position="float" orientation="portrait"><caption><p>se1c01024_si_001.pdf</p></caption></media></supplementary-material></sec><notes notes-type="" id="notes2"><title>Author Contributions</title><p>The manuscript
was written through contributions from all authors. All authors have
given approval to the final version of the manuscript.</p></notes><notes notes-type="funding-statement" id="notes3"><p>This work was
supported by funding from the Germany Research Council (DFG WA2804).
This project has received funding in part (T.N. and J.M.M.) from the
European Research Council (ERC) under the European Union&#8217;s
Horizon 2020 research and innovation program under grant agreement
no. 743077 (ThermalMR).</p></notes><notes notes-type="COI-statement" id="NOTES-d7e2322-autogenerated"><p>The authors declare no
competing financial interest.</p></notes><ack><title>Acknowledgments</title><p>The authors would
like to thank Dr. Peter Schmieder
(FMP) for supporting the NMR analysis of the compounds.</p></ack><glossary id="dl1"><def-list><title>Abbreviations</title><def-item><term><sup>19</sup>F</term><def><p>fluorine-19</p></def></def-item><def-item><term>1H</term><def><p>hydrogen-1/proton</p></def></def-item><def-item><term>bSSFP</term><def><p>balanced steady-state
free precession</p></def></def-item><def-item><term>CF3</term><def><p>trifluoromethyl</p></def></def-item><def-item><term>CFSE</term><def><p>carboxyfluoresceinsuccinimidylester</p></def></def-item><def-item><term>DCIP</term><def><p>dichloroindophenol</p></def></def-item><def-item><term>DHODH</term><def><p>dihydroorotate dehydrogenase</p></def></def-item><def-item><term>DMSO</term><def><p>dimethylsulfoxide</p></def></def-item><def-item><term>FA</term><def><p>flip angle</p></def></def-item><def-item><term>FID</term><def><p>free induction decay</p></def></def-item><def-item><term>FOV</term><def><p>field of view</p></def></def-item><def-item><term>FWHM</term><def><p>full width at
half maximum</p></def></def-item><def-item><term>IC<sub>50</sub></term><def><p>inhibitory concentration (50%)</p></def></def-item><def-item><term><sc>l</sc>-DHO</term><def><p><sc>l</sc>-dihydroorotate</p></def></def-item><def-item><term>MR</term><def><p>magnetic resonance</p></def></def-item><def-item><term>MRI</term><def><p>magnetic resonance imaging</p></def></def-item><def-item><term>MS</term><def><p>multiple sclerosis</p></def></def-item><def-item><term>PBMCs</term><def><p>peripheral blood
mononuclear cells</p></def></def-item><def-item><term>PSF</term><def><p>point-spread-function</p></def></def-item><def-item><term>RARE</term><def><p>rapid acquisition with relaxation enhancement</p></def></def-item><def-item><term>RF</term><def><p>radiofrequency</p></def></def-item><def-item><term>RT</term><def><p>room temperature</p></def></def-item><def-item><term>SF5</term><def><p>pentafluorosulfanyl</p></def></def-item><def-item><term>SNR</term><def><p>signal-to-noise
ratio</p></def></def-item><def-item><term>TA</term><def><p>acquisition
time</p></def></def-item><def-item><term>TE</term><def><p>echo time</p></def></def-item><def-item><term>TF</term><def><p>teriflunomide</p></def></def-item><def-item><term>TR</term><def><p>repetition time</p></def></def-item><def-item><term>UTE</term><def><p>ultrashort echo
time</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name name-style="western"><surname>Ruiz-Cabello</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Barnett</surname><given-names>B. P.</given-names></name>; <name name-style="western"><surname>Bottomley</surname><given-names>P. A.</given-names></name>; <name name-style="western"><surname>Bulte</surname><given-names>J. W. M.</given-names></name><article-title>Fluorine 19F
MRS and MRI in biomedicine</article-title>. <source>NMR Biomed.</source><year>2011</year>, <volume>24</volume>, <fpage>114</fpage>&#8211;<lpage>129</lpage>. <pub-id pub-id-type="doi">10.1002/nbm.1570</pub-id>.<pub-id pub-id-type="pmid">20842758</pub-id><pub-id pub-id-type="pmcid">PMC3051284</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name name-style="western"><surname>Reid</surname><given-names>D. G.</given-names></name>; <name name-style="western"><surname>Murphy</surname><given-names>P. S.</given-names></name><article-title>Fluorine magnetic resonance in vivo: a powerful tool
in the study of drug distribution and metabolism</article-title>. <source>Drug Discovery Today</source><year>2008</year>, <volume>13</volume>, <fpage>473</fpage>&#8211;<lpage>480</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2007.12.011</pub-id>.<pub-id pub-id-type="pmid">18549972</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name name-style="western"><surname>Muller</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Faeh</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Diederich</surname><given-names>F.</given-names></name><article-title>Fluorine in
pharmaceuticals: looking
beyond intuition</article-title>. <source>Science</source><year>2007</year>, <volume>317</volume>, <fpage>1881</fpage>&#8211;<lpage>1886</lpage>. <pub-id pub-id-type="doi">10.1126/science.1131943</pub-id>.<pub-id pub-id-type="pmid">17901324</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Sanchez-Rosello</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Acena</surname><given-names>J. L.</given-names></name>; <name name-style="western"><surname>del Pozo</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Sorochinsky</surname><given-names>A. E.</given-names></name>; <name name-style="western"><surname>Fustero</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Soloshonok</surname><given-names>V. A.</given-names></name>; <name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><article-title>Fluorine in pharmaceutical
industry: fluorine-containing drugs introduced to the market in the
last decade (2001-2011)</article-title>. <source>Chem. Rev.</source><year>2014</year>, <volume>114</volume>, <fpage>2432</fpage>&#8211;<lpage>2506</lpage>. <pub-id pub-id-type="doi">10.1021/cr4002879</pub-id>.<pub-id pub-id-type="pmid">24299176</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="book" id="cit5"><person-group person-group-type="allauthors"><name name-style="western"><surname>Niendorf</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Ji</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Waiczies</surname><given-names>S.</given-names></name></person-group>, <article-title>Chapter 11 Fluorinated Natural
Compounds and Synthetic Drugs</article-title>. In <source>Fluorine
Magnetic Resonance Imaging</source>, <edition>1 ed</edition>.; <person-group person-group-type="editor"><name name-style="western"><surname>Ahrens</surname><given-names>E. T.</given-names></name>; <name name-style="western"><surname>Fl&#246;gel</surname><given-names>U.</given-names></name></person-group> Ed. <publisher-name>Pan Stanford
Publishing</publisher-name>: <year>2016</year>; pp. <fpage>311</fpage>&#8211;<lpage>344</lpage>, <pub-id pub-id-type="doi">10.1201/9781315364605-12</pub-id>.</mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name name-style="western"><surname>Wolf</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Presant</surname><given-names>C. A.</given-names></name>; <name name-style="western"><surname>Waluch</surname><given-names>V.</given-names></name><article-title>19F-MRS studies of
fluorinated drugs
in humans</article-title>. <source>Adv. Drug Delivery Rev.</source><year>2000</year>, <volume>41</volume>, <fpage>55</fpage>&#8211;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/S0169-409X(99)00056-3</pub-id>.<pub-id pub-id-type="pmid">10699305</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Viel</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Ziarelli</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Peng</surname><given-names>L.</given-names></name><article-title>19F NMR: a
valuable
tool for studying biological events</article-title>. <source>Chem. Soc.
Rev.</source><year>2013</year>, <volume>42</volume>, <fpage>7971</fpage>&#8211;<lpage>7982</lpage>. <pub-id pub-id-type="doi">10.1039/c3cs60129c</pub-id>.<pub-id pub-id-type="pmid">23864138</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name name-style="western"><surname>Bartusik</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Aebisher</surname><given-names>D.</given-names></name><article-title>19F applications in
drug development and imaging -
a review</article-title>. <source>Biomed. Pharmacother.</source><year>2014</year>, <volume>68</volume>, <fpage>813</fpage>&#8211;<lpage>817</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2014.07.012</pub-id>.<pub-id pub-id-type="pmid">25107839</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name name-style="western"><surname>Ahrens</surname><given-names>E. T.</given-names></name>; <name name-style="western"><surname>Helfer</surname><given-names>B. M.</given-names></name>; <name name-style="western"><surname>O&#8217;Hanlon</surname><given-names>C. F.</given-names></name>; <name name-style="western"><surname>Schirda</surname><given-names>C.</given-names></name><article-title>Clinical cell therapy
imaging using a perfluorocarbon tracer and fluorine-19 MRI</article-title>. <source>Magn Reson Med</source><year>2014</year>, <volume>72</volume>, <fpage>1696</fpage>&#8211;<lpage>1701</lpage>. <pub-id pub-id-type="doi">10.1002/mrm.25454</pub-id>.<pub-id pub-id-type="pmid">25241945</pub-id><pub-id pub-id-type="pmcid">PMC4253123</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name name-style="western"><surname>Kieger</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Wiester</surname><given-names>M. J.</given-names></name>; <name name-style="western"><surname>Procissi</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Parrish</surname><given-names>T. B.</given-names></name>; <name name-style="western"><surname>Mirkin</surname><given-names>C. A.</given-names></name>; <name name-style="western"><surname>Thaxton</surname><given-names>C. S.</given-names></name><article-title>Hybridization-induced
&#8243;off-on&#8243; 19F-NMR
signal probe release from DNA-functionalized gold nanoparticles</article-title>. <source>Small</source><year>2011</year>, <volume>7</volume>, <fpage>1977</fpage>&#8211;<lpage>1981</lpage>. <pub-id pub-id-type="doi">10.1002/smll.201100566</pub-id>.<pub-id pub-id-type="pmid">21661107</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Li</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Han</surname><given-names>F. Y.</given-names></name>; <name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Tan</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Fu</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Xu</surname><given-names>Z. P.</given-names></name>; <name name-style="western"><surname>Whittaker</surname><given-names>A. K.</given-names></name><article-title>Integrating
Fluorinated Polymer and
Manganese-Layered Double Hydroxide Nanoparticles as pH-activated 19F
MRI Agents for Specific and Sensitive Detection of Breast Cancer</article-title>. <source>Small</source><year>2019</year>, <volume>15</volume>, <elocation-id>e1902309</elocation-id><pub-id pub-id-type="doi">10.1002/smll.201902309</pub-id>.<pub-id pub-id-type="pmid">31328398</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name name-style="western"><surname>Waiczies</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Lepore</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Drechsler</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Qadri</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Purfurst</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Sydow</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Dathe</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Kuhne</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Lindel</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Hoffmann</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Pohlmann</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Niendorf</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Waiczies</surname><given-names>S.</given-names></name><article-title>Visualizing
brain inflammation with a shingled-leg radio-frequency head probe
for 19F/1H MRI</article-title>. <source>Sci. Rep.</source><year>2013</year>, <volume>3</volume>, <fpage>1280</fpage><pub-id pub-id-type="doi">10.1038/srep01280</pub-id>.<pub-id pub-id-type="pmid">23412352</pub-id><pub-id pub-id-type="pmcid">PMC3573344</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name name-style="western"><surname>Fl&#246;gel</surname><given-names>U.</given-names></name>; <name name-style="western"><surname>Ding</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Hardung</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Jander</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Reichmann</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Jacoby</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Schubert</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Schrader</surname><given-names>J.</given-names></name><article-title>In vivo monitoring
of inflammation after cardiac and cerebral ischemia by fluorine magnetic
resonance imaging</article-title>. <source>Circulation</source><year>2008</year>, <volume>118</volume>, <fpage>140</fpage>&#8211;<lpage>148</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.737890</pub-id>.<pub-id pub-id-type="pmid">18574049</pub-id><pub-id pub-id-type="pmcid">PMC2735653</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name name-style="western"><surname>Yu</surname><given-names>J. X.</given-names></name>; <name name-style="western"><surname>Hallac</surname><given-names>R. R.</given-names></name>; <name name-style="western"><surname>Chiguru</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Mason</surname><given-names>R. P.</given-names></name><article-title>New frontiers and
developing applications in 19F NMR</article-title>. <source>Prog. Nucl.
Magn. Reson. Spectrosc.</source><year>2013</year>, <volume>70</volume>, <fpage>25</fpage>&#8211;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1016/j.pnmrs.2012.10.001</pub-id>.<pub-id pub-id-type="pmid">23540575</pub-id><pub-id pub-id-type="pmcid">PMC3613763</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name name-style="western"><surname>Bolo</surname><given-names>N. R.</given-names></name>; <name name-style="western"><surname>Hode</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Nedelec</surname><given-names>J. F.</given-names></name>; <name name-style="western"><surname>Laine</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Wagner</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Macher</surname><given-names>J. P.</given-names></name><article-title>Brain pharmacokinetics
and tissue distribution in vivo
of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy</article-title>. <source>Neuropsychopharmacology</source><year>2000</year>, <volume>23</volume>, <fpage>428</fpage>&#8211;<lpage>438</lpage>. <pub-id pub-id-type="doi">10.1016/S0893-133X(00)00116-0</pub-id>.<pub-id pub-id-type="pmid">10989270</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name name-style="western"><surname>Prinz</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Starke</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Millward</surname><given-names>J. M.</given-names></name>; <name name-style="western"><surname>Fillmer</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Delgado</surname><given-names>P. R.</given-names></name>; <name name-style="western"><surname>Waiczies</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Pohlmann</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Rothe</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Nazare</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Paul</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Niendorf</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Waiczies</surname><given-names>S.</given-names></name><article-title>In vivo detection of
teriflunomide-derived fluorine signal during neuroinflammation using
fluorine MR spectroscopy</article-title>. <source>Theranostics</source><year>2021</year>, <volume>11</volume>, <fpage>2490</fpage>&#8211;<lpage>2504</lpage>. <pub-id pub-id-type="doi">10.7150/thno.47130</pub-id>.<pub-id pub-id-type="pmid">33456555</pub-id><pub-id pub-id-type="pmcid">PMC7806491</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name name-style="western"><surname>Wiese</surname><given-names>M. D.</given-names></name>; <name name-style="western"><surname>Rowland</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Polasek</surname><given-names>T. M.</given-names></name>; <name name-style="western"><surname>Sorich</surname><given-names>M. J.</given-names></name>; <name name-style="western"><surname>O&#8217;Doherty</surname><given-names>C.</given-names></name><article-title>Pharmacokinetic
evaluation of teriflunomide for the treatment of multiple sclerosis</article-title>. <source>Expert Opin Drug Metab Toxicol</source><year>2013</year>, <volume>9</volume>, <fpage>1025</fpage>&#8211;<lpage>1035</lpage>. <pub-id pub-id-type="doi">10.1517/17425255.2013.800483</pub-id>.<pub-id pub-id-type="pmid">23682862</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name name-style="western"><surname>Waiczies</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Millward</surname><given-names>J. M.</given-names></name>; <name name-style="western"><surname>Starke</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Delgado</surname><given-names>P. R.</given-names></name>; <name name-style="western"><surname>Huelnhagen</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Prinz</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Marek</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Wecker</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Wissmann</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Koch</surname><given-names>S. P.</given-names></name>; <name name-style="western"><surname>Boehm-Sturm</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Waiczies</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Niendorf</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Pohlmann</surname><given-names>A.</given-names></name><article-title>Enhanced Fluorine-19
MRI Sensitivity using a Cryogenic
Radiofrequency Probe: Technical Developments and Ex Vivo Demonstration
in a Mouse Model of Neuroinflammation</article-title>. <source>Sci.
Rep.</source><year>2017</year>, <volume>7</volume>, <fpage>9808</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-09622-2</pub-id>.<pub-id pub-id-type="pmid">28851959</pub-id><pub-id pub-id-type="pmcid">PMC5575026</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name name-style="western"><surname>Sowaileh</surname><given-names>M. F.</given-names></name>; <name name-style="western"><surname>Hazlitt</surname><given-names>R. A.</given-names></name>; <name name-style="western"><surname>Colby</surname><given-names>D. A.</given-names></name><article-title>Application of the
Pentafluorosulfanyl
Group as a Bioisosteric Replacement</article-title>. <source>ChemMedChem</source><year>2017</year>, <volume>12</volume>, <fpage>1481</fpage>&#8211;<lpage>1490</lpage>. <pub-id pub-id-type="doi">10.1002/cmdc.201700356</pub-id>.<pub-id pub-id-type="pmid">28782186</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name name-style="western"><surname>Adolphi</surname><given-names>N. L.</given-names></name>; <name name-style="western"><surname>Kuethe</surname><given-names>D. O.</given-names></name><article-title>Quantitative mapping of ventilation-perfusion
ratios
in lungs by 19F MR imaging of T1 of inert fluorinated gases</article-title>. <source>Magn Reson Med</source><year>2008</year>, <volume>59</volume>, <fpage>739</fpage>&#8211;<lpage>746</lpage>. <pub-id pub-id-type="doi">10.1002/mrm.21579</pub-id>.<pub-id pub-id-type="pmid">18383306</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name name-style="western"><surname>H&#229;kansson</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Javed</surname><given-names>M. A.</given-names></name>; <name name-style="western"><surname>Komulainen</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Holden</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Hasell</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Cooper</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Lantto</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Telkki</surname><given-names>V. V.</given-names></name><article-title>NMR relaxation
and modelling study of the dynamics of SF(6) and Xe in porous organic
cages</article-title>. <source>Phys. Chem. Chem. Phys.</source><year>2019</year>, <volume>21</volume>, <fpage>24373</fpage>&#8211;<lpage>24382</lpage>. <pub-id pub-id-type="doi">10.1039/C9CP04379A</pub-id>.<pub-id pub-id-type="pmid">31663555</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name name-style="western"><surname>Couch</surname><given-names>M. J.</given-names></name>; <name name-style="western"><surname>Ball</surname><given-names>I. K.</given-names></name>; <name name-style="western"><surname>Li</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Fox</surname><given-names>M. S.</given-names></name>; <name name-style="western"><surname>Biman</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Albert</surname><given-names>M. S.</given-names></name><article-title>19F MRI of the Lungs Using Inert Fluorinated Gases:
Challenges and New Developments</article-title>. <source>J Magn Reson
Imaging</source><year>2019</year>, <volume>49</volume>, <fpage>343</fpage>&#8211;<lpage>354</lpage>. <pub-id pub-id-type="doi">10.1002/jmri.26292</pub-id>.<pub-id pub-id-type="pmid">30248212</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name name-style="western"><surname>Bassetto</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Ferla</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Pertusati</surname><given-names>F.</given-names></name><article-title>Polyfluorinated
groups in medicinal
chemistry</article-title>. <source>Future Med. Chem.</source><year>2015</year>, <volume>7</volume>, <fpage>527</fpage>&#8211;<lpage>546</lpage>. <pub-id pub-id-type="doi">10.4155/fmc.15.5</pub-id>.<pub-id pub-id-type="pmid">25875877</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name name-style="western"><surname>Wolf</surname><given-names>U.</given-names></name>; <name name-style="western"><surname>Scholz</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Heussel</surname><given-names>C. P.</given-names></name>; <name name-style="western"><surname>Markstaller</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Schreiber</surname><given-names>W. G.</given-names></name><article-title>Subsecond fluorine-19 MRI of the lung</article-title>. <source>Magn Reson Med</source><year>2006</year>, <volume>55</volume>, <fpage>948</fpage>&#8211;<lpage>951</lpage>. <pub-id pub-id-type="doi">10.1002/mrm.20859</pub-id>.<pub-id pub-id-type="pmid">16534836</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name name-style="western"><surname>Kuethe</surname><given-names>D. O.</given-names></name>; <name name-style="western"><surname>Caprihan</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Gach</surname><given-names>H. M.</given-names></name>; <name name-style="western"><surname>Lowe</surname><given-names>I. J.</given-names></name>; <name name-style="western"><surname>Fukushima</surname><given-names>E.</given-names></name><article-title>Imaging obstructed
ventilation with NMR using inert fluorinated gases</article-title>. <source>J. Appl. Physiol.</source><year>2000</year>, <volume>88</volume>, <fpage>2279</fpage>&#8211;<lpage>2286</lpage>. <pub-id pub-id-type="doi">10.1152/jappl.2000.88.6.2279</pub-id>.<pub-id pub-id-type="pmid">10846046</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name name-style="western"><surname>Baumgartner</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Walloschek</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Kralik</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Gotschlich</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Tasler</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Mies</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Leban</surname><given-names>J.</given-names></name><article-title>Dual binding mode of
a novel series of DHODH inhibitors</article-title>. <source>J. Med.
Chem.</source><year>2006</year>, <volume>49</volume>, <fpage>1239</fpage>&#8211;<lpage>1247</lpage>. <pub-id pub-id-type="doi">10.1021/jm0506975</pub-id>.<pub-id pub-id-type="pmid">16480261</pub-id></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name name-style="western"><surname>Bonomo</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Tosco</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Giorgis</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Lolli</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Fruttero</surname><given-names>R.</given-names></name><article-title>The role of
fluorine in stabilizing the bioactive conformation of dihydroorotate
dehydrogenase inhibitors</article-title>. <source>J. Mol. Model.</source><year>2013</year>, <volume>19</volume>, <fpage>1099</fpage>&#8211;<lpage>1107</lpage>. <pub-id pub-id-type="doi">10.1007/s00894-012-1643-5</pub-id>.<pub-id pub-id-type="pmid">23143678</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name name-style="western"><surname>Westphal</surname><given-names>M. V.</given-names></name>; <name name-style="western"><surname>Wolfstadter</surname><given-names>B. T.</given-names></name>; <name name-style="western"><surname>Plancher</surname><given-names>J. M.</given-names></name>; <name name-style="western"><surname>Gatfield</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Carreira</surname><given-names>E. M.</given-names></name><article-title>Evaluation
of tert-butyl isosteres: case studies of physicochemical and pharmacokinetic
properties, efficacies, and activities</article-title>. <source>ChemMedChem</source><year>2015</year>, <volume>10</volume>, <fpage>461</fpage>&#8211;<lpage>469</lpage>. <pub-id pub-id-type="doi">10.1002/cmdc.201402502</pub-id>.<pub-id pub-id-type="pmid">25630804</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="patent" id="cit29"><person-group person-group-type="allauthors"><name name-style="western"><surname>Avrutov</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Gershon</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Liberman</surname><given-names>A.</given-names></name></person-group><article-title>Method
for synthesizing
leflunomide</article-title>. Patent <year>2002</year>, <patent>US20020022646A1</patent></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name name-style="western"><surname>Frantz</surname><given-names>D. E.</given-names></name>; <name name-style="western"><surname>Weaver</surname><given-names>D. G.</given-names></name>; <name name-style="western"><surname>Carey</surname><given-names>J. P.</given-names></name>; <name name-style="western"><surname>Kress</surname><given-names>M. H.</given-names></name>; <name name-style="western"><surname>Dolling</surname><given-names>U. H.</given-names></name><article-title>Practical
synthesis of aryl triflates under aqueous conditions</article-title>. <source>Org. Lett.</source><year>2002</year>, <volume>4</volume>, <fpage>4717</fpage>&#8211;<lpage>4718</lpage>. <pub-id pub-id-type="doi">10.1021/ol027154z</pub-id>.<pub-id pub-id-type="pmid">12489969</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="patent" id="cit31"><person-group person-group-type="allauthors"><name name-style="western"><surname>Palle</surname><given-names>V. R.</given-names></name>; <name name-style="western"><surname>Bhat</surname><given-names>R. P.</given-names></name>; <name name-style="western"><surname>Kaliappan</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Babu</surname><given-names>J.
R.</given-names></name>; <name name-style="western"><surname>Shanmughasamy</surname><given-names>R.</given-names></name></person-group><article-title>A novel process
for the preparation of teriflunomide</article-title>. Patent <year>2016</year>, <patent>WO 2016203410 A1</patent></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name name-style="western"><surname>Sainas</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Pippione</surname><given-names>A. C.</given-names></name>; <name name-style="western"><surname>Giorgis</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Lupino</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Goyal</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Ramondetti</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Buccinn&#224;</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Piccinini</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Braga</surname><given-names>R. C.</given-names></name>; <name name-style="western"><surname>Andrade</surname><given-names>C. H.</given-names></name>; <name name-style="western"><surname>Andersson</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Moritzer</surname><given-names>A.-C.</given-names></name>; <name name-style="western"><surname>Friemann</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Mensa</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Al-Kadaraghi</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Boschi</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Lolli</surname><given-names>M. L.</given-names></name><article-title>Design, synthesis, biological evaluation
and X-ray structural studies of potent human dihydroorotate dehydrogenase
inhibitors based on hydroxylated azole scaffolds</article-title>. <source>Eur. J. Med. Chem.</source><year>2017</year>, <volume>129</volume>, <fpage>287</fpage>&#8211;<lpage>302</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2017.02.017</pub-id>.<pub-id pub-id-type="pmid">28235702</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal" id="cit33"><name name-style="western"><surname>Ladds</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>van Leeuwen</surname><given-names>I. M. M.</given-names></name>; <name name-style="western"><surname>Drummond</surname><given-names>C. J.</given-names></name>; <name name-style="western"><surname>Chu</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Healy</surname><given-names>A. R.</given-names></name>; <name name-style="western"><surname>Popova</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Pastor Fernandez</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Mollick</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Darekar</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Sedimbi</surname><given-names>S. K.</given-names></name>; <name name-style="western"><surname>Nekulova</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Sachweh</surname><given-names>M. C. C.</given-names></name>; <name name-style="western"><surname>Campbell</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Higgins</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Tuck</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Popa</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Safont</surname><given-names>M. M.</given-names></name>; <name name-style="western"><surname>Gelebart</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Fandalyuk</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Thompson</surname><given-names>A. M.</given-names></name>; <name name-style="western"><surname>Svensson</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Gustavsson</surname><given-names>A. L.</given-names></name>; <name name-style="western"><surname>Johansson</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Farnegardh</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Yngve</surname><given-names>U.</given-names></name>; <name name-style="western"><surname>Saleh</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Haraldsson</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>D&#8217;Hollander</surname><given-names>A.
C. A.</given-names></name>; <name name-style="western"><surname>Franco</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Hakansson</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Walse</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Larsson</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Peat</surname><given-names>E. M.</given-names></name>; <name name-style="western"><surname>Pelechano</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Lunec</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Vojtesek</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Carmena</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Earnshaw</surname><given-names>W. C.</given-names></name>; <name name-style="western"><surname>McCarthy</surname><given-names>A. R.</given-names></name>; <name name-style="western"><surname>Westwood</surname><given-names>N. J.</given-names></name>; <name name-style="western"><surname>Arsenian-Henriksson</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Lane</surname><given-names>D. P.</given-names></name>; <name name-style="western"><surname>Bhatia</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>McCormack</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Lain</surname><given-names>S.</given-names></name><article-title>A DHODH inhibitor increases p53 synthesis and enhances tumor cell
killing by p53 degradation blockage</article-title>. <source>Nat. Commun.</source><year>2018</year>, <volume>9</volume>, <fpage>1107</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-03441-3</pub-id>.<pub-id pub-id-type="pmid">29549331</pub-id><pub-id pub-id-type="pmcid">PMC5856786</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal" id="cit34"><name name-style="western"><surname>Knecht</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>L&#246;ffler</surname><given-names>M.</given-names></name><article-title>Species-related inhibition of human
and rat dihydroorotate
dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives</article-title>. <source>Biochem. Pharmacol.</source><year>1998</year>, <volume>56</volume>, <fpage>1259</fpage>&#8211;<lpage>1264</lpage>. <pub-id pub-id-type="doi">10.1016/S0006-2952(98)00145-2</pub-id>.<pub-id pub-id-type="pmid">9802339</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal" id="cit35"><name name-style="western"><surname>Copeland</surname><given-names>R. A.</given-names></name>; <name name-style="western"><surname>Davis</surname><given-names>J. P.</given-names></name>; <name name-style="western"><surname>Dowling</surname><given-names>R. L.</given-names></name>; <name name-style="western"><surname>Lombardo</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Murphy</surname><given-names>K. B.</given-names></name>; <name name-style="western"><surname>Patterson</surname><given-names>T. A.</given-names></name><article-title>Recombinant human dihydroorotate dehydrogenase: expression,
purification, and characterization of a catalytically functional truncated
enzyme</article-title>. <source>Arch. Biochem. Biophys.</source><year>1995</year>, <volume>323</volume>, <fpage>79</fpage>&#8211;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1006/abbi.1995.0012</pub-id>.<pub-id pub-id-type="pmid">7487077</pub-id></mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal" id="cit36"><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Delohery</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Arendt</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Jones</surname><given-names>C.</given-names></name><article-title>The effects
of teriflunomide on lymphocyte subpopulations in human peripheral
blood mononuclear cells in vitro</article-title>. <source>J. Neuroimmunol.</source><year>2013</year>, <volume>265</volume>, <fpage>82</fpage>&#8211;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneuroim.2013.10.003</pub-id>.<pub-id pub-id-type="pmid">24182769</pub-id></mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal" id="cit37"><name name-style="western"><surname>Lyons</surname><given-names>A. B.</given-names></name><article-title>Analysing
cell division in vivo and in vitro using flow cytometric measurement
of CFSE dye dilution</article-title>. <source>J. Immunol. Methods</source><year>2000</year>, <volume>243</volume>, <fpage>147</fpage>&#8211;<lpage>154</lpage>. <pub-id pub-id-type="doi">10.1016/S0022-1759(00)00231-3</pub-id>.<pub-id pub-id-type="pmid">10986412</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="book" id="cit38"><person-group person-group-type="allauthors"><name name-style="western"><surname>Faber</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Schmid</surname><given-names>F.</given-names></name></person-group><article-title>Chapter
1 Pulse
Sequence Considerations and Schemes</article-title>. In <source>Fluorine
Magnetic Resonance Imaging</source>, <person-group person-group-type="editor"><name name-style="western"><surname>Ahrens</surname><given-names>E. T.</given-names></name>; <name name-style="western"><surname>Fl&#246;gel</surname><given-names>U.</given-names></name></person-group> Ed. <publisher-name>Pan Stanford
Publishing</publisher-name>: <year>2016</year>; pp. <fpage>3</fpage>&#8211;<lpage>27</lpage>, <pub-id pub-id-type="doi">10.1201/9781315364605-2</pub-id>.</mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal" id="cit39"><name name-style="western"><surname>Mastropietro</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>De Bernardi</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Breschi</surname><given-names>G. L.</given-names></name>; <name name-style="western"><surname>Zucca</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Cametti</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Soffientini</surname><given-names>C. D.</given-names></name>; <name name-style="western"><surname>de Curtis</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Terraneo</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Metrangolo</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Spreafico</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Resnati</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Baselli</surname><given-names>G.</given-names></name><article-title>Optimization of rapid
acquisition with relaxation enhancement (RARE) pulse sequence parameters
for 19F-MRI studies</article-title>. <source>J Magn Reson Imaging</source><year>2014</year>, <volume>40</volume>, <fpage>162</fpage>&#8211;<lpage>170</lpage>. <pub-id pub-id-type="doi">10.1002/jmri.24347</pub-id>.<pub-id pub-id-type="pmid">25050436</pub-id></mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal" id="cit40"><name name-style="western"><surname>Zhang</surname><given-names>J. H.</given-names></name>; <name name-style="western"><surname>Chung</surname><given-names>T. D. Y.</given-names></name>; <name name-style="western"><surname>Oldenburg</surname><given-names>K. R.</given-names></name><article-title>A Simple Statistical Parameter for
Use in Evaluation and Validation of High Throughput Screening Assays</article-title>. <source>J Biomol Screen</source><year>1999</year>, <volume>4</volume>, <fpage>67</fpage>&#8211;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1177/108705719900400206</pub-id>.<pub-id pub-id-type="pmid">10838414</pub-id></mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal" id="cit41"><name name-style="western"><surname>Prinz</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Delgado</surname><given-names>P. R.</given-names></name>; <name name-style="western"><surname>Eigentler</surname><given-names>T. W.</given-names></name>; <name name-style="western"><surname>Starke</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Niendorf</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Waiczies</surname><given-names>S.</given-names></name><article-title>Toward 19F magnetic
resonance thermometry: spin-lattice
and spin-spin-relaxation times and temperature dependence of fluorinated
drugs at 9.4 T</article-title>. <source>MAGMA</source><year>2019</year>, <volume>32</volume>, <fpage>51</fpage>&#8211;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1007/s10334-018-0722-8</pub-id>.<pub-id pub-id-type="pmid">30515642</pub-id></mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="book" id="cit42"><person-group person-group-type="allauthors"><name name-style="western"><surname>Starke</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Niendorf</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Waiczies</surname><given-names>S.</given-names></name></person-group>, <article-title>Data Preparation
Protocol for Low Signal-to-Noise Ratio Fluorine-19 MRI</article-title>. In <source>Preclinical MRI of the Kidney: Methods and Protocols</source>, <person-group person-group-type="editor"><name name-style="western"><surname>Pohlmann</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Niendorf</surname><given-names>T.</given-names></name></person-group>, Eds. <publisher-name>Springer US</publisher-name>: <publisher-loc>New York, NY</publisher-loc>, <year>2021</year>; pp. <fpage>711</fpage>&#8211;<lpage>722</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-0716-0978-1_43</pub-id><pub-id pub-id-type="pmcid">PMC9703253</pub-id><pub-id pub-id-type="pmid">33476033</pub-id></mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal" id="cit43"><name name-style="western"><surname>Schindelin</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Arganda-Carreras</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Frise</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Kaynig</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Longair</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Pietzsch</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Preibisch</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Rueden</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Saalfeld</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Schmid</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Tinevez</surname><given-names>J. Y.</given-names></name>; <name name-style="western"><surname>White</surname><given-names>D. J.</given-names></name>; <name name-style="western"><surname>Hartenstein</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Eliceiri</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Tomancak</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Cardona</surname><given-names>A.</given-names></name><article-title>Fiji: an open-source
platform for biological-image analysis</article-title>. <source>Nat.
Methods</source><year>2012</year>, <volume>9</volume>, <fpage>676</fpage>&#8211;<lpage>682</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id>.<pub-id pub-id-type="pmid">22743772</pub-id><pub-id pub-id-type="pmcid">PMC3855844</pub-id></mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal" id="cit44"><name name-style="western"><surname>Stump</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Eberle</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Schweizer</surname><given-names>W. B.</given-names></name>; <name name-style="western"><surname>Kaiser</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Brun</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Krauth-Siegel</surname><given-names>R. L.</given-names></name>; <name name-style="western"><surname>Lentz</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Diederich</surname><given-names>F.</given-names></name><article-title>Pentafluorosulfanyl
as a novel building block for enzyme inhibitors: trypanothione reductase
inhibition and antiprotozoal activities of diarylamines</article-title>. <source>ChemBioChem</source><year>2009</year>, <volume>10</volume>, <fpage>79</fpage>&#8211;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1002/cbic.200800565</pub-id>.<pub-id pub-id-type="pmid">19058274</pub-id></mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal" id="cit45"><name name-style="western"><surname>Warnke</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Stuve</surname><given-names>O.</given-names></name>; <name name-style="western"><surname>Kieseier</surname><given-names>B. C.</given-names></name><article-title>Teriflunomide
for the treatment of
multiple sclerosis</article-title>. <source>Clin Neurol Neurosurg</source><year>2013</year>, <volume>115 Suppl 1</volume>, <fpage>S90</fpage>&#8211;<lpage>S94</lpage>. <pub-id pub-id-type="doi">10.1016/j.clineuro.2013.09.030</pub-id>.<pub-id pub-id-type="pmid">24321165</pub-id></mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="book" id="cit46"><person-group person-group-type="allauthors"><name name-style="western"><surname>Dolbier</surname><given-names>W. R.</given-names></name></person-group>, <source>Guide to fluorine
NMR for organic chemists</source>. <edition>2 ed.</edition>; <publisher-name>Wiley</publisher-name>: <publisher-loc>Hoboken, N.J</publisher-loc>., <year>2016</year>.</mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal" id="cit47"><name name-style="western"><surname>Kadayakkara</surname><given-names>D. K.</given-names></name>; <name name-style="western"><surname>Damodaran</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Hitchens</surname><given-names>T. K.</given-names></name>; <name name-style="western"><surname>Bulte</surname><given-names>J. W. M.</given-names></name>; <name name-style="western"><surname>Ahrens</surname><given-names>E. T.</given-names></name><article-title><sup>19</sup>F spin-lattice
relaxation of perfluoropolyethers: Dependence on temperature
and magnetic field strength (7.0-14.1T)</article-title>. <source>J.
Magn. Reson.</source><year>2014</year>, <volume>242</volume>, <fpage>18</fpage>&#8211;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmr.2014.01.014</pub-id>.<pub-id pub-id-type="pmid">24594752</pub-id><pub-id pub-id-type="pmcid">PMC4008704</pub-id></mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal" id="cit48"><name name-style="western"><surname>Dalvit</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Vulpetti</surname><given-names>A.</given-names></name><article-title>Fluorine-protein interactions
and (1)(9)F NMR isotropic
chemical shifts: An empirical correlation with implications for drug
design</article-title>. <source>ChemMedChem</source><year>2011</year>, <volume>6</volume>, <fpage>104</fpage>&#8211;<lpage>114</lpage>. <pub-id pub-id-type="doi">10.1002/cmdc.201000412</pub-id>.<pub-id pub-id-type="pmid">21117131</pub-id></mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal" id="cit49"><name name-style="western"><surname>Aime</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Botta</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Fasano</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Terreno</surname><given-names>E.</given-names></name><article-title>Lanthanide(III) chelates
for NMR biomedical applications</article-title>. <source>Chem. Soc.
Rev.</source><year>1998</year>, <volume>27</volume>, <fpage>19</fpage>&#8211;<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1039/A827019Z</pub-id>.</mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal" id="cit50"><name name-style="western"><surname>de
Vries</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Moonen</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Yildirim</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Langereis</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Lamerichs</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Pikkemaat</surname><given-names>J. A.</given-names></name>; <name name-style="western"><surname>Baroni</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Terreno</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Nicolay</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Strijkers</surname><given-names>G. J.</given-names></name>; <name name-style="western"><surname>Grull</surname><given-names>H.</given-names></name><article-title>Relaxometric studies
of gadolinium-functionalized perfluorocarbon nanoparticles for MR
imaging</article-title>. <source>Contrast Media Mol. Imaging</source><year>2014</year>, <volume>9</volume>, <fpage>83</fpage>&#8211;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1002/cmmi.1541</pub-id>.<pub-id pub-id-type="pmid">24470297</pub-id></mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="journal" id="cit51"><name name-style="western"><surname>N&#246;th</surname><given-names>U.</given-names></name>; <name name-style="western"><surname>Morrissey</surname><given-names>S. P.</given-names></name>; <name name-style="western"><surname>Deichmann</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Jung</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Adolf</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Haase</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Lutz</surname><given-names>J.</given-names></name><article-title>Perfluoro-15-Crown-5-Ether Labelled
Macrophages in Adoptive Transfer Experimental Allergic Encephalomyelitis</article-title>. <source>Artif Cells Blood Substit Immobil Biotechnol</source><year>1997</year>, <volume>25</volume>, <fpage>243</fpage>&#8211;<lpage>254</lpage>. <pub-id pub-id-type="doi">10.3109/10731199709118914</pub-id>.<pub-id pub-id-type="pmid">9167839</pub-id></mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal" id="cit52"><name name-style="western"><surname>Jansen</surname><given-names>J. F. A.</given-names></name>; <name name-style="western"><surname>Backes</surname><given-names>W. H.</given-names></name>; <name name-style="western"><surname>Nicolay</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Kooi</surname><given-names>M. E.</given-names></name><article-title>1H MR spectroscopy
of the brain: absolute quantification of metabolites</article-title>. <source>Radiology</source><year>2006</year>, <volume>240</volume>, <fpage>318</fpage>&#8211;<lpage>332</lpage>. <pub-id pub-id-type="doi">10.1148/radiol.2402050314</pub-id>.<pub-id pub-id-type="pmid">16864664</pub-id></mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal" id="cit53"><name name-style="western"><surname>Dubois</surname><given-names>B. W.</given-names></name>; <name name-style="western"><surname>Evers</surname><given-names>A. S.</given-names></name><article-title>Fluorine-19 NMR
spin-spin relaxation (T2) method for
characterizing volatile anesthetic binding to proteins. Analysis of
isoflurane binding to serum albumin</article-title>. <source>Biochemistry</source><year>1992</year>, <volume>31</volume>, <fpage>7069</fpage>&#8211;<lpage>7076</lpage>. <pub-id pub-id-type="doi">10.1021/bi00146a007</pub-id>.<pub-id pub-id-type="pmid">1643040</pub-id></mixed-citation></ref><ref id="ref54"><mixed-citation publication-type="journal" id="cit54"><name name-style="western"><surname>Kremenchutzky</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Freedman</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Bar-Or</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Dukovic</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Benamor</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Truffinet</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Connor</surname><given-names>P.</given-names></name><article-title>12-Year Clinical Efficacy
and Safety
Data for Teriflunomide: Results from a Phase 2 Extension Study (P7.223)</article-title>. <source>Neurology</source><year>2015</year>, <volume>84</volume>, <fpage>P7.223</fpage>.</mixed-citation></ref><ref id="ref55"><mixed-citation publication-type="journal" id="cit55"><name name-style="western"><surname>Freedman</surname><given-names>M. S.</given-names></name>; <name name-style="western"><surname>Bar-Or</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Benamor</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Truffinet</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Poole</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Mandel</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Kremenchutzky</surname><given-names>M.</given-names></name><article-title>Long-term
Disability Outcomes in Patients Treated With Teriflunomide for up
to 14 Years: Group- and Patient-Level Data From the Phase 2 Extension
Study (P6.389)</article-title>. <source>Neurology</source><year>2018</year>, <volume>90</volume>, <fpage>P6.389</fpage>.</mixed-citation></ref></ref-list></back></article></pmc-articleset>